Beyond Air, Inc. (XAIR)

Beyond Air, Inc.'s stock (XAIR) has experienced several notable events in the past six months. The company reported mixed Q2 and Q3 2026 earnings, with EPS missing estimates but revenue sometimes beating expectations. Dan Moorhead was appointed as CFO, succeeding interim CFO Duke Drewell. The sale of its NeuroNOS subsidiary to XTL Biopharmaceuticals was halted. Steve Lisi resigned as CEO, and Robert Goodman was appointed as his successor. Beyond Air received a Nasdaq notice for failing to meet the minimum bid price requirement and faces potential delisting, with a special stockholder meeting scheduled to approve another reverse stock split. The stock has experienced a significant decline, trading near its 52-week low.

Analysis of Beyond Air, Inc.'s seasonal charts suggests a period of seasonal strength for the Healthcare sector from April 25 to December 4. However, only 9 years of data are available for XAIR, which may be insufficient to create a fully reliable seasonal profile for the company.

Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company in the Healthcare sector, focusing on the LungFit platform, a Nitric Oxide (NO) Generator and Delivery System. The company's products include LungFit PH, an FDA-approved device for persistent pulmonary hypertension of the newborn (PPHN); LungFit PRO, an investigational device for viral lung infections; LungFit GO, an investigational device for nontuberculous mycobacteria (NTM) lung infections; ultra-high concentration Nitric Oxide (UNO) therapy in Phase 1 clinical trial for tumors; and a selective neuronal nitric oxide synthase (nNOS) inhibitor under development for neurological conditions and autism spectrum disorder.

Beyond Air, Inc. is headquartered in Garden City, New York, United States, and has been expanding its international presence. As of December 2025, its distribution network for the LungFit PH system spans 39 countries, covering a population exceeding three billion people. Recent expansions include new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, El Salvador, France, Turkey, Romania, Morocco, Germany, Brazil, Austria, the Netherlands, and Sri Lanka.

Beyond Air's reputation in the past year has likely been significantly impacted by its financial performance and operational challenges. The stock has experienced a substantial decline, and the Nasdaq delisting notice could severely affect investor confidence. Despite these challenges, the company has reported revenue growth and expanded its global distribution network, which could positively contribute to its operational reputation.

Beyond Air, Inc. has a mix of institutional and individual owners. As of May 1, 2026, there were 25 institutional owners holding a total of 1,480,712 shares, including Alyeska Investment Group, L.P., Balyasny Asset Management Llc, and Vanguard Group Inc. Key individual owners include Robert Carey, Steven A. Lisi, and Ari Raved.